Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia – examination of practice in Germany

By Steinmetz T.   Totzke U.   Söling U.   Groschek M.   Mittermüller J.   Schweigert M.   Tesch H.   Nawka S.   Schmitz S.   Tsamaloukas A.  

Current Medical Research and Opinion, Vol. 24, Iss. 10, 2008-10 ,pp. : 2751-2756

Informa Healthcare

Access to resources Recommend Favorite

Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis‐stimulating agents and transfusion in patients with chemotherapy‐induced anaemia

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 3, 2015-06 ,pp. : 299-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite

Use and cost of erythropoiesis-stimulating agents in patients with cancer

By Daniel Gregory   Hurley Dana   Whyte Joanna L.   Willey Vincent   Wilson Marcus   Kallich Joel  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1775-1784

Informa Healthcare

Access to resources Recommend Favorite

The Effect of Erythropoiesis-Stimulating Agents in Patients with Therapy-Refractory Autoimmune Hemolytic Anemia

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 6, 2014-09 ,pp. : 462-468

Karger

Access to resources Recommend Favorite